Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions regarding the SmithKline Beecham Employee Benefit Trust ("the Trust") on February 20, 2007:
- Share Sale: 727 Ordinary shares were sold on behalf of a participant in the SmithKline Beecham Annual Investment Plan at a price of GBP 14.93 per share.
- Share Transfer: 2,425 Ordinary shares were transferred from the Trust to a participant in the SmithKline Beecham Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J S Heslop holds an interest in the fund shares in the same capacity as other beneficiaries.
Investor Verification Checklist
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following these transactions.
- Confirm the current share price relative to the GBP 14.93 transaction price reported on February 20, 2007.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding Director interests.